Evaxion Cost Of Revenue from 2010 to 2024

EVAX Stock  USD 1.15  0.04  3.36%   
Evaxion Biotech Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue will likely drop to 106.40 in 2024. During the period from 2010 to 2024, Evaxion Biotech Cost Of Revenue regression line of annual values had r-squared of  0.08 and arithmetic mean of  122,037. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
112
Current Value
106.4
Quarterly Volatility
145.8 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 1.4 M, Depreciation And Amortization of 330.1 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 206, Dividend Yield of 0.0 or Days Sales Outstanding of 4.3 K. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
  
Check out the analysis of Evaxion Biotech Correlation against competitors.

Latest Evaxion Biotech's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Evaxion Biotech AS over the last few years. Cost of Revenue is found on Evaxion Biotech AS income statement and represents the costs associated with goods and services Evaxion Biotech provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Evaxion Biotech's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evaxion Biotech's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Pretty Stable
   Cost Of Revenue   
       Timeline  

Evaxion Cost Of Revenue Regression Statistics

Arithmetic Mean122,037
Geometric Mean42,835
Coefficient Of Variation119.50
Mean Deviation89,426
Median80,984
Standard Deviation145,830
Sample Variance21.3B
Range571.2K
R-Value0.28
Mean Square Error21.2B
R-Squared0.08
Significance0.32
Slope9,016
Total Sum of Squares297.7B

Evaxion Cost Of Revenue History

2024 106.4
2023 112.0
2022571.3 K
2021343.5 K
2020105.7 K

About Evaxion Biotech Financial Statements

Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue 112.00  106.40 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Evaxion Stock Analysis

When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.